BioCryst Reports Q4 2025 Revenue Rise, Stock Falls BioCryst reported Q4 2025 revenue of $102.3m (up 28% YoY) and FY2026 guidance of $440–460m; shares fell ~7% on Mar 28–29, 2026 after the earnings call.

BioCryst Reports Q4 2025 Revenue Rise, Stock Falls: BioCryst reported Q4 2025 revenue of $102.3m (up 28% YoY) and FY2026 guidance of $440–460m; shares fell ~7% on Mar 28–29, 2026 after the earnings call. 👈 Read full analysis #BioCryst #EarningsReport #StockMarket #RevenueGrowth #FY2026

BioCryst 2025 Slides Map Path to $1B BioCryst's 2025 slides set a $1.0bn revenue target; Investing.com reported on Mar 28, 2026, signalling portfolio shifts and Navenibart expansion that warrant reworked models.

BioCryst 2025 Slides Map Path to $1B: BioCryst's 2025 slides set a $1.0bn revenue target; Investing.com reported on Mar 28, 2026, signalling portfolio shifts and Navenibart expansion that warrant reworked… 👈 Read full analysis #BioCryst #RevenueGrowth #Pharmaceuticals #Investing #MarketAnalysis

#HereditaryAngioedema #HAE #HAECommunity #Orladeyo #BioCryst #HaeAwareness #LivingRare #ChronicIllnessCommunity #RareDiseaseAwareness #HAECare #OralTherapy #HealthInnovation #RareDiseaseCommunity #ChronicIllnessAwareness #BioNews #AngioedemaNews

Ademi Firm Launches Investigation into Astria Therapeutics Shareholder Deal for Potential Legal Breaches The Ademi Firm is investigating Astria Therapeutics for potential fiduciary breaches in a transaction. Shareholders may be affected as details emerge.

Ademi Firm Launches Investigation into Astria Therapeutics Shareholder Deal for Potential Legal Breaches #USA #Milwaukee #Ademi_Firm #Astria_Therapeutics #BioCryst

Neopharmed buys Euro rights to BioCryst's HAE drug Orladeyo Neopharmed Gentili buys BioCryst's hereditary angioedema drug Orladeyo in Europe, the first stage of an international expansion for the Italian firm.

#BioCryst has agreed to sell its European business based on #hereditaryangioedema therapy Orladeyo to Italy's #NeopharmedGentili in a #deal valued at $250 million upfront.

pharmaphorum.com/news/neophar...

BioCryst stock rises after $264 million sale of European ORLADEYO business Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Click Subscribe #BioCryst #ORLADEYO #Investing #Pharmaceuticals #StockMarket